StreetInsider.com News Articles

RBC Capital Starts AstraZeneca (AZN:LN) (AZN) at Outperform

Wed, 09 Sep 2026 03:37:03 -0400

RBC Capital analyst Trung Huynh initiates coverage on AstraZeneca (AZN:LN) (NASDAQ: AZN) with a Outperform rating and a price target of GBP145.00.

The analyst comments: “We initiate at Outperform with a 14,500p PT. AZN offers the most compelling risk/reward in our EU Pharma coverage. We believe the stock has been overly punished by recent concerns, Wainua's ATTR-failure, the BMY pursuit raising growth questions, and looming SERENA-4/AVANZAR (2H26) uncertainty, driving the multiple to 14x P/E, a 10-year low. While SERENA-4/AVANZAR will likely keep risk-averse investors sidelined, the setup is favorable: low expectations, modest NPV risk, and unnecessary for AZN's $80bn target. We

RBC Capital Starts AstraZeneca (AZN:LN) (AZN) at Outperform

Wed, 09 Sep 2026 03:37:03 -0400

RBC Capital analyst Trung Huynh initiates coverage on AstraZeneca (AZN:LN) (NASDAQ: AZN) with a Outperform rating and a price target of GBP145.00.

RBC Capital Starts AstraZeneca (AZN:LN) (AZN) at Outperform

Wed, 09 Sep 2026 03:37:03 -0400

RBC Capital analyst Trung Huynh initiates coverage on AstraZeneca (AZN:LN) (NASDAQ: AZN) with a Outperform rating and a price target of GBP145.00.

RBC Capital Starts AstraZeneca (AZN:LN) (AZN) at Outperform

Wed, 09 Sep 2026 03:37:03 -0400

RBC Capital analyst Trung Huynh initiates coverage on AstraZeneca (AZN:LN) (NASDAQ: AZN) with a Outperform rating and a price target of GBP145.00.

RBC Capital Starts AstraZeneca (AZN:LN) (AZN) at Outperform

Wed, 09 Sep 2026 03:37:03 -0400

RBC Capital analyst Trung Huynh initiates coverage on AstraZeneca (AZN:LN) (NASDAQ: AZN) with a Outperform rating and a price target of GBP145.00.

RBC Capital Starts AstraZeneca (AZN:LN) (AZN) at Outperform

Wed, 09 Sep 2026 03:37:03 -0400

RBC Capital analyst Trung Huynh initiates coverage on AstraZeneca (AZN:LN) (NASDAQ: AZN) with a Outperform rating and a price target of GBP145.00.

Form 6-K ASTRAZENECA PLC For: Sep 08

Tue, 08 Sep 2026 09:05:00 -0400

si-local-file:///var/storage/secattach/20260908/27034311.html

Imfinzi plus tarlatamab shows survival gains in lung cancer trial

Tue, 08 Sep 2026 09:01:25 -0400

AstraZeneca's (NYSE: AZN) Imfinzi (durvalumab), combined with Amgen's tarlatamab, demonstrated a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) compared with Imfinzi alone as a first-line maintenance treatment in patients with extensive-stage small cell lung cancer (ES-SCLC), according to a planned interim analysis of the Phase III DeLLphi-305 trial.

The trial enrolled patients with ES-SCLC who had not progressed following induction treatment with Imfinzi combined with platinum-based chemotherapy and etoposide. A total of 563 patients were randomized 1:1 to receive either Imfinzi plus tarlatamab or Imfinzi alone. The combination also showed a statistically significant improvement in objective response

Imfinzi plus tarlatamab shows survival gains in lung cancer trial

Tue, 08 Sep 2026 09:01:25 -0400

IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-sta

Tue, 08 Sep 2026 09:00:00 -0400

IMFINZI is the first and only immunotherapy in combination with a bispecific T-cell engager to show survival benefit in this setting

DeLLphi-305 Phase III trial results reinforce IMFINZI as the backbone immunotherapy for small cell lung cancer across stages of disease

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) versus IMFINZI alone as a 1st-line maintenance treatment. The trial included patients with extensive-stage small cell lung cancer (ES-SCLC) who

IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-sta

Tue, 08 Sep 2026 09:00:00 -0400

IMFINZI is the first and only immunotherapy in combination with a bispecific T-cell engager to show survival benefit in this setting

DeLLphi-305 Phase III trial results reinforce IMFINZI as the backbone immunotherapy for small cell lung cancer across stages of disease

AstraZeneca COPD drug tozorakimab cuts exacerbations in Phase III trials

Tue, 08 Sep 2026 07:50:54 -0400

AstraZeneca (LSE/STO/NYSE: AZN) reported that its drug tozorakimab reduced moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations in two Phase III trials, with full results published in the New England Journal of Medicine and presented at the European Respiratory Society Congress 2026.

In the OBERON trial, tozorakimab 300mg administered once every four weeks reduced exacerbations by 29% in former smokers and 30% in the overall population of current and former smokers, compared with placebo. In the TITANIA trial, reductions were 34% in former smokers and 29% in the overall population. A total of 2,306 patients were randomized across both trials.

AstraZeneca COPD drug tozorakimab cuts exacerbations in Phase III trials

Tue, 08 Sep 2026 07:50:54 -0400

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

Tue, 08 Sep 2026 07:50:00 -0400

Tozorakimab showed clinically meaningful benefits across blood eosinophil thresholds

Full results published in the New England Journal of Medicine and presented at the European Respiratory Society Congress 2026

Tozorakimab Biologics License Application accepted under Priority Review in US for patients with COPD

WILMINGTON, Del.--(BUSINESS WIRE)-- Full results from the positive Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically significant and highly clinically meaningful efficacy in reducing moderate and severe exacerbations in a broad population of patients with chronic obstructive pulmonary disease (COPD) still experiencing exacerbations while on inhaled standard

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

Tue, 08 Sep 2026 07:50:00 -0400

Tozorakimab showed clinically meaningful benefits across blood eosinophil thresholds

Full results published in the New England Journal of Medicine and presented at the European Respiratory Society Congress 2026

Tozorakimab Biologics License Application accepted under Priority Review in US for patients with COPD

Form 6-K ASTRAZENECA PLC For: Sep 08

Tue, 08 Sep 2026 06:29:00 -0400

si-local-file:///var/storage/secattach/20260908/27032786.html

AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP160 at Barclays

Tue, 08 Sep 2026 05:38:06 -0400

Barclays analyst James Gordon lowered the price target on AstraZeneca (AZN:LN) (NASDAQ: AZN) to GBP160.00 (from GBP165.00) while maintaining a Overweight rating.

AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP160 at Barclays

Tue, 08 Sep 2026 05:38:06 -0400

Barclays analyst James Gordon lowered the price target on AstraZeneca (AZN:LN) (NASDAQ: AZN) to GBP160.00 (from GBP165.00) while maintaining a Overweight rating.

AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP160 at Barclays

Tue, 08 Sep 2026 05:38:06 -0400

Barclays analyst James Gordon lowered the price target on AstraZeneca (AZN:LN) (NASDAQ: AZN) to GBP160.00 (from GBP165.00) while maintaining a Overweight rating.

AstraZeneca (AZN:LN) (AZN) PT Lowered to GBP160 at Barclays

Tue, 08 Sep 2026 05:38:06 -0400

Barclays analyst James Gordon lowered the price target on AstraZeneca (AZN:LN) (NASDAQ: AZN) to GBP160.00 (from GBP165.00) while maintaining a Overweight rating.

FDA grants accelerated approval to AstraZeneca's camizestrant combo

Mon, 07 Sep 2026 17:55:39 -0400

The U.S. Food and Drug Administration has granted accelerated approval to AstraZeneca's (NYSE: AZN) ETCAMAH (camizestrant) in combination with a CDK4/6 inhibitor for the treatment of adult patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer, upon detection of an ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy.

The approval covers use alongside three CDK4/6 inhibitors: abemaciclib, palbociclib, or ribociclib. Detection of the ESR1 mutation must be confirmed using an FDA-authorized test. Concurrently, the FDA approved a companion diagnostic to detect emerging ESR1 resistance mutations in circulating tumor DNA.

The accelerated approval was based on results from the SERENA-6

FDA grants accelerated approval to AstraZeneca's camizestrant combo

Mon, 07 Sep 2026 17:55:39 -0400

The accelerated approval was based on results from the SERENA-6

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

Fri, 04 Sep 2026 19:03:00 -0400

Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumor mutation

Innovative treatment strategy has potential to reshape 1st-line treatment paradigm for patients in this setting

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s ETCAMAH® (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor (AI) and CDK4/6

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

Fri, 04 Sep 2026 19:03:00 -0400

Approval based on SERENA-6 Phase III trial results which showed combination reduced the risk of disease progression or death by 56% in patients with an emergent ESR1 tumor mutation

Innovative treatment strategy has potential to reshape 1st-line treatment paradigm for patients in this setting

FDA approves AstraZeneca breast cancer drug Etcamah via accelerated path

Fri, 04 Sep 2026 15:41:44 -0400

The U.S. Food and Drug Administration granted accelerated approval to AstraZeneca's Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer who develop an estrogen receptor-1 (ESR1) mutation during treatment.

According to a statement from the FDA, the approval is based on detection of the ESR1 resistance mutation using an authorized test. ESR1 mutations occur in fewer than 5% of patients at the time of initial HR-positive metastatic breast cancer diagnosis but are present in nearly 40% of patients after disease progression on an aromatase inhibitor.

The FDA described the approval